VA
IMVT icon

Vident Advisory’s Immunovant IMVT Stock Holding History

Vident Advisory’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224K Buy
+9,011
New +$233K ﹤0.01% 1636

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vident Advisory's IMVT Position: Q1 2026 in Review

Vident Advisory opened a new position in Immunovant (IMVT) in Q1 2026: 9,011 shares worth $224K. The stake represents ﹤0.01% of the portfolio and ranks #1636 among its holdings.

215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Vident Advisory held 9,011 shares of Immunovant worth $224K as of Q1 2026.
  • Immunovant was a new Vident Advisory position in Q1 2026.
  • Immunovant made up ﹤0.01% of Vident Advisory's portfolio in Q1 2026, its #1636 holding.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.